Keyword: Regeneron Pharmaceuticals
Fasinumab cleared the efficacy bar but triggered safety alarms, keeping it on the tail of Pfizer and Eli Lilly’s rival drug without dispelling doubts.
Regenxbio's gene therapy for wet age-related macular degeneration (AMD) reduced the need for in-eye injections of anti-VEGF drugs.
The pact combines Regeneron’s antibody expertise with Bluebird’s cell therapy toolkit to expand the list of tumors modified T cells can treat.
Molecular Partners has rejigged its team, hiring Pamela Trail from Regeneron to serve as CSO and shunting Michael Stumpp across to the COO position.
Decibel Therapeutics raised $55 million in a series C round and named Vir Biotechnology CEO George Scangos as chair of its board of directors.
At BIO, we chatted with Doug Ingram about Sarepta's pipeline, its latest hires and how the healthcare landscape must change.
Sarepta brought on Biogen’s VP of late-stage programs, Gilmore O’Neill, as chief medical officer, after their previous hire left after 8 months.
Our rolling live blog for all the biotech news that's fit to print from J.P. Morgan. Check here frequently for ongoing updates.
The project will see Regeneron sequence the exomes of 500,000 Britons with the financial backing of AbbVie, Alnylam, AstraZeneca, Biogen and Pfizer.
Regeneron and Sanofi’s PD-1 candidate cemiplimab will be tested alongside a human papillomavirus (HPV) targeting drug from Dutch biotech ISA Pharma.